MedTrace Logo

An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07783009 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-08-24

No results posted yet for this study

Summary

The purpose of this expanded access program (EAP) is to provide early access to divarasib to participants with KRAS G12C-positive (KRAS G12C+) advanced or metastatic non-small cell lung cancer (NSCLC), prior to divarasib becoming commercially available in the United States.

Conditions

Interventions

DRUG

Divarasib

Participants will self-administer divarasib as per the schedule in the protocol.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07783009 on ClinicalTrials.gov